Corcept Therapeutics Incorporated (CORT) exhibits 96.0% gross margins and 4.8% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 95.0x enterprise multiple and 6.5% implied options volatility.
Sustained 96.0% gross profitability converts into 5.9% operating margin and 4.8% ROIC, outpacing sector cost of capital.
ROIC: 4.8% // GM: 96.0%YoY revenue trajectory of +12.8% paired with 1.53% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +12.8% // FCF YLD: 1.53%Altman Z-Score of 26.00 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 8/9Trading at 93.2x trailing P/E (78.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 93.2x // EV/EBITDA: 95.0xOptions market prices a ±6.5% implied move with a 0.79 put/call ratio around $84.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.79Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 13.1% net margins.
NET MARGIN: 13.1% // D/E: 0.12x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CORT & activate live FRED threshold breach alerts.